The Phase 2b study of CSL112 in subjects with acute myocardial infarction (AMI) is designed to evaluate the safety and tolerability of CSL112. This multicenter, randomized, double-blind, placebo-controlled trial involves multiple doses of CSL112 at different levels to assess their effects on liver and kidney function compared to a placebo. The study aims to ensure that CSL112 can be administered safely to patients who have experienced a heart attack.
[button title=”Read Study” link=”https://clinicaltrials.gov/study/NCT02108262″ target=”_blank” align=”” icon=”” icon_position=”” color=”” font_color=”” size=”2″ full_width=”” class=”” download=”” rel=””]